Deutsche Bank upgraded Alvotech (ALVO) to Buy from Hold with a $14 price target The firm believes the company offers “scarcity value” in the biosimilar market, which “remains within its infancy.” Alvotech is well positioned to benefit from the sector’s opportunity, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALVO: